|
Evaluation of Quality of Life from Chemotherapy Induced Peripheral Neuropathy in Solid Cancer Patients |
|---|---|
| รหัสดีโอไอ | |
| Creator | Nonthikun Pasukmmon |
| Title | Evaluation of Quality of Life from Chemotherapy Induced Peripheral Neuropathy in Solid Cancer Patients |
| Contributor | Manit Sae-teaw, Saran Kitsaran, Jitlada Juengsamarn, Wassana Mathong, Tharatip Chansophonphon |
| Publisher | Faculty of Pharmaceutical Sciences KKU MSU UBU |
| Publication Year | 2565 |
| Journal Title | Isan Journal ofPharmaceutical Sciences |
| Journal Vol. | 18 |
| Journal No. | 1 |
| Page no. | 58-69 |
| Keyword | peripheral neuropathy, quality of life, cancer patients, peripheral neuropathy severity, chemotherapy |
| URL Website | https://tci-thaijo.org/index.php/IJPS |
| Website title | Isan Journal ofPharmaceutical Sciences,IJPS |
| ISSN | 19050852 |
| Abstract | Peripheral neuropathy is a common adverse drug reaction following treatment with chemotherapy. This adverse drug reaction and its severity affect treatment efficacy and quality of life of cancer patients. The study objective was to compare the quality of life scores change from chemotherapy-induced peripheral neuropathy between low severity group (grade 0-1) and moderate severity or higher group (grade 2 or higher). Materials and Method: The prospective cohort study was conducted in solid tumors patients who received chemotherapy at the chemotherapy patient care unit, Sunpasitthiprasong Hospital, Ubon Ratchathani Province from 1 August 2020 to 31 January 2021. The Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Thai version (EORTC QLQ-CIPN20) was used for the evaluation of peripheral neuropathy related quality of life. Common Terminology Criteria for Adverse Events (CTCAE version 5.0) was used for assessing peripheral neuropathy severity. Comparing change of quality of life between between low severity group and moderate severity or higher group peripheral neuropathy using Mann Whitney U-test. Results: Seventy patients were enrolled. Forty-seven patients (67.14%) had peripheral neuropathy. Sensory neuropathy was reported majorly type in 41 patients (58.57%) and 12 patients (29.27%) had moderate severity or higher. The median overall quality of life score change was significantly increased in moderate severity or higher (12.22 (Interquartile rang 11.11)) compared with low severity group (3.33 (Interquartile rang 6.67)) (P-value < 0.001). The change in sensory quality of life and motor quality of life score were also significantly increased in moderate severity or higher group. Thus, Conclusion: peripheral neuropathy has high severity after chemotherapy treatment, and resulting poorer quality of life. |
